Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- TMEM-173 N-Terminal Methionine-Proline-Tyrosine-Serine plasma membrane tetraspanner IRF3 IRF-3 IFN NET-23 R-232 NFkB H-232 TBK-1 escherichia immuno-modulatory mutant
- Product Overview:
STING M284 variant (human, recombinant) contains amino acids 138-379 of the wild-type variant (R232) with a methionine substituted for arginine at position 284. Stimulator of interferon genes (STING) is a component of the innate immune response that binds to cyclic dinucleotides, which are bacterial second messengers, leading to activation of NF-?B and transcription of immunomodulatory genes, including type I interferon (IFN).{22400,22401,24611,24607} The R232 variant of STING is the most common variant in the human population, found at a frequency of 57.9% in the 1000 Genome Project.{38697} The SNP variant H232 is found at a 13.7% frequency. The R284M mutation in STING is associated with constitutive activation of downstream signaling. It increases the propensity of STING to dimerize and associate with the kinase TBK1, enhancing the ability of STING to activate IRF3 and NF-?B and induce a type I IFN response.{41454} However, the R284M mutation occurs outside of the dimerization region between positions 153-177, so rather than a direct effect on dimerization, it is predicted to promote or inhibit binding of a cellular factor that stabilizes or impairs STING dimerization.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.